Summary. Adult female mice, regardless of the stage of the oestrous cycle, were super\x=req-\ ovulated with PMSG and hCG. Ovulated oocytes were recovered 20\p=n-\22h after hCG and fertilized ova 72\p=n-\74h after hCG. Compared with the controls, the gonadotrophin treatment increased the mating rate of the females, and the incidence of abnormal ova. Regardless of the site of gonadotrophin injections, the numbers of ova were equal, but the proportion of abnormal eggs in mice injected intraperitoneally was significantly higher than in mice injected subcutaneously.
Introduction
Gonadotrophin treatment of female mice results in ovulation of large numbers of oocytes. As compared with spontaneous ovulation, superovulation is associated with a lower rate of fertiliz¬ ation and a higher loss of embryos during pregnancy (Gates, 1956 (Gates, , 1971 Fowler & Edwards, 1957 , 1960 ; Edwards & Gates, 1959 ; Allen & McLaren, 1971 ; Beaumont & Smith, 1975) . Little is known about the mechanisms involved, and attempts to synchronize exogenous administration of gonadotrophins with endogenous hormonal events have not resulted in better embryo survival (Beaumont & Smith, 1975) .
We have performed a quantitative and morphological analysis on superovulated ova of mice to determine how route of gonadotrophin treatment affects the normality of the resulting oocytes and embryos. Materials and Methods Virgin female mice of the inbred CBA-T6T6 strain, aged [10] [11] [12] weeks, were used. The animals were kept in a room with alternating periods of 16 h of light and 8 h of darkness (lights on 08:00 h). All animals, those treated with gonadotrophin and the untreated controls, were picked randomly regardless of the stage of the oestrous cycle. Food and water were given ad libitum.
For superovulation, mice were injected with 5 i.u. PMSG (Gestyl; N.V. Organon, Oss, The Netherlands; or Sigma Chemical Co., St Louis, MO, U.S.A.) followed 48 h later by 5 i.u. hCG (Pregnyl; N.V. Organon). The gonadotrophins were diluted in NaCl-phosphate buffer (140 mM-NaCl, 10 mM-sodium phosphate, pH 7-2) and administered intraperitoneally or subcutaneously. The injections were timed between 10:00 h and 12:00 h.
At 7-9 h after hCG each female was caged with one fertile male overnight. Mating was confirmed 13-15 h later by the presence of a vaginal plug. The numbers of superovulated oocytes were determined separately for two groups of females: those which were caged with a male but did not mate, and those which were not caged with a male.
Oocytes were recovered 22-24 h after hCG by dissecting the oviducts and ova from the mated females 72-74 h after hCG by flushing the uteri and dissecting the oviducts in medium (Lehtonen, 1985) . Oocytes were characterized as cumulus-covered or cumulus-free and as normal or abnormal. Hyaluronidase was used for removing cumulus cells (Lehtonen, 1985 (Table 1) . This difference is not significant (P > 0-1). There was no difference (P > 01) between the mean numbers of ova after subcutaneous and intraperitoneal injections. Nearly all (98%) of the oocytes were surrounded by cumulus cells, while 2% were free of cumulus; the site of injection did not affect this relationship, and there was no difference between the paired and non-paired females (Tables 1 and  2 ).
Influence of site ofgonadotrophin administration on the proportion of abnormal oocytes
The proportions of normal and abnormal oocytes are presented in Table 1 . After subcutaneous administration of gonadotrophins, 7-5% of the cells in paired females were cumulus-covered but abnormal, and after intraperitoneal administration, 14-5% (P < 001). This difference in incidence of oocyte abnormality was similar in the unpaired females (Table 1) .
Influence ofgonadotrophin treatment on mating and fertilization frequency Superovulation caused nearly a 3-fold increase in mating frequency, but a slight reduction in the relative proportion of pregnancies on Day 13 post coitum (Table 2 ). harvested from females that were paired with males but had not mated and from females that were not paired. (Allen & McLaren, 1971) in the gonadotrophin-treated group (Table 5 ). The proportions of abnormal ova and 1-cell ova in this series were similar to those presented in Table 4 . Two-cell ova found 72-74 h after hCG should obviously be considered as having arrested cleavage and abnormal (Table 5 ).
Discussion
The oocyte yields recovered after gonadotrophin treatment were as expected. Gonadotrophin treatment of adult mice results in a 3-fold increase in the number of ovulated oocytes (Fowler & Edwards, 1957 , 1960 Edwards & Gates, 1959; Edwards et ai, 1963; Runner & Palm, 1953; Lin & Bailey, 1965; Beaumont & Smith, 1975; Ito et ai, 1981) . In this study, oocytes were not collected from spontaneously ovulating females, but at 72-74 h after hCG the number of ova in super¬ ovulated females was about 3 times that of untreated females.
Several attempts have been made to maximize superovulation yields (Edwards et ai, 1963; Gates, 1971; Beaumont & Smith, 1975) . Beaumont & Smith (1975) synchronized the adminis¬ tration of gonadotrophins with the innate oestrous cycle by timing the administration of hCG to coincide with the endogenous LH surge, which resulted in a 2-fold increase in the number of ova on Day 2 post coitum. In the present study we found a 3-fold increase in the number of oocytes at the same developmental stage (72-74 h after hCG). Compared with the result of Beaumont & Smith (1975) , this increase is surprisingly high, as the females were picked randomly regardless of the stage of oestrous cycle. One possible explanation for this is a difference between the mouse strains used (Lin & Bailey, 1965; McLaren, 1967; Luckett & Mukherjee, 1986) . Alternatively, the most responsive stage of the oestrous cycle to the superovulatory treatment has not yet been identified.
In this study, the gonadotrophin-treated females that were paired but did not mate produced slightly lower numbers of oocytes than did non-paired females. This is not surprising, as both the number of oocytes and the mating activity in superovulated females are probably similarly connected with the stage of the innate oestrous cycle.
In connection with superovulation, there is an increase in fragmented, degenerate and denuded oocytes (Beaumont & Smith, 1975; Miller & Armstrong, 1981a, b; Walton & Armstrong, 1981; Walton et ai, 1983; Moor et ai, 1985; present study). The mechanisms by which superovulation increases the incidence of abnormal ova are not clear. Three explanations have been put forward. Degeneration and fragmentation take place gradually in ageing ova. Any abnormality in the cumulus-free oocytes could result from ageing as they were presumably ovulated due to the PMSG injection. Second, at 72-74 h in our study a considerable proportion of the ova appeared to have been activated, but were undergoing degeneration and fragmentation. It is therefore possible that in some ova degenerative changes occur as a result of failure in fertilization (Walton et ai, 1983) , possibly owing to imbalance in the concentrations of oestrogen and progesterone (Fowler & Edwards, 1960; Harrington, 1965; Jutaro et ai, 1982) . Tesh (1966) and Fujimoto et ai (1974) have proposed that gonadotrophin treatment produces genetic defects in the ova. At present it is not possible to differentiate between the above possibilities. However, adminis¬ tration of gonadotrophins intraperitoneally increases the proportion of abnormal ova more than does subcutaneous administration. To our knowledge, this aspect has not been thoroughly studied, although Gates (1971) noted that virtually no difference could be detected between the two routes of gonadotrophin administration, and that intraperitoneal injection has been preferred in the interest of convenience. The mechanisms by which the intraperitoneal route of gonadotrophin treatment increases the incidence of abnormality are not known, but our results suggest that sub¬ cutaneous rather than intraperitoneal administration of gonadotrophins should be used for superovulation of mice.
